Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Since metastatic colorectal cancer (CRC) is a leading cause of cancer-related death, therapeutic approaches overcoming primary and acquired therapy resistance are an urgent medical need. In this study, the efficacy and toxicity of high-affinity inhibitors targeting antiapoptotic BCL-2 proteins (BCL-...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherr, Anna-Lena, Mock, Andreas, Gdynia, Georg, Schmitt, Nathalie, Heilig, Christoph E., Korell, Felix, Rhadakrishnan, Praveen, Hoffmeister, Paula, Metzeler, Klaus H., Schulze-Osthoff, Klaus, Illert, Anna L., Boerries, Melanie, Trojan, Jörg, Waidmann, Oliver, Falkenhorst, Johanna, Siveke, Jens, Jost, Philipp J., Bitzer, Michael, Malek, Nisar P., Vecchione, Loredana, Jelas, Ivan, Brors, Benedikt, Glimm, Hanno, Stenzinger, Albrecht, Grekova, Svetlana P., Gehrig, Tobias, Schulze-Bergkamen, Henning, Jäger, Dirk, Schirmacher, Peter, Heikenwalder, Mathias, Goeppert, Benjamin, Schneider, Martin, Fröhling, Stefan, Köhler, Bruno C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568722/
https://www.ncbi.nlm.nih.gov/pubmed/33070156
http://dx.doi.org/10.1038/s41419-020-03092-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568722/
https://www.ncbi.nlm.nih.gov/pubmed/33070156
http://dx.doi.org/10.1038/s41419-020-03092-7

Ejemplares similares